Sugi Predict

Sugi Predict / Targets / ENTPD8

ENTPD8

Ectonucleoside triphosphate diphosphohydrolase 8 · Q5MY95 · ENTPD8 on Sugi Atlas →

0 patent compounds predicted against ENTPD8, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to ENTPD8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation PHASE3UNKNOWN
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) PHASE1/PHASE2RECRUITING
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer PHASE2RECRUITING
University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial PHASE1/PHASE2COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia PHASE1/PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors PHASE1COMPLETED
A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors PHASE1WITHDRAWN
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors PHASE1COMPLETED
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients EARLY_PHASE1RECRUITING
Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders nanUNKNOWN
Genetics of Middle Ear Disease nanCOMPLETED
Genome Environment Microbiome and Metabolome in Autism Study nanCOMPLETED
PCD New Gene Discovery nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study nanRECRUITING
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts nanCOMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED
Genetics of Primary Ciliary Dyskinesia nanCOMPLETED
Genetic Feature of Congenital Hearing Loss in Chinese Population nanNOT_YET_RECRUITING
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation nanCOMPLETED
A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors nanWITHDRAWN
Whole Genome Scan of Extended Families With Familial Vocal Cord Paralysis nanCOMPLETED
Pathophysiology of Paget's Disease of Bone nanCOMPLETED
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer nanCOMPLETED
Identification of an Asthma Susceptibility Gene on 3P nanCOMPLETED
EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study) nanRECRUITING
Epigenetics, DNA Methylation Patterns and Periodontal Disease nanCOMPLETED
Histoblood Group Antigens as a Risk Factor of Asthma nanCOMPLETED
Registry and Natural History of Epilepsy-Dyskinesia Syndromes nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a ENTPD8 binder may also engage these)

ProteinNameSimilarity
O35795 — 0.993 O35795 →
A0JND9 — 0.992 A0JND9 →
ENTPD2 Ectonucleoside triphosphate diphosphohydrolase 2 0.991 landscape →
Q5DRK1 — 0.991 Q5DRK1 →
O55026 — 0.985 O55026 →
Q8K0L2 — 0.983 Q8K0L2 →
O93295 — 0.965 O93295 →
P97687 — 0.961 P97687 →
Q32M88 — 0.960 Q32M88 →
P79784 — 0.959 P79784 →
Q9WUZ9 — 0.959 Q9WUZ9 →
Q9QYC8 — 0.958 Q9QYC8 →
Q9MYU4 — 0.958 Q9MYU4 →
Q8BP56 — 0.957 Q8BP56 →
Q6P6S9 — 0.957 Q6P6S9 →
Q9QXE5 — 0.957 Q9QXE5 →
Q0VD19 — 0.955 Q0VD19 →
ITGA5 Integrin alpha-5 0.954 landscape →
ENTPD5 Nucleoside diphosphate phosphatase ENTPD5 0.953 landscape →
P55772 — 0.953 P55772 →
ITGA2B Integrin alpha-IIb 0.953 landscape →
E1BPW0 — 0.953 E1BPW0 →
D3ZLH5 — 0.953 D3ZLH5 →
SMPD1 Sphingomyelin phosphodiesterase 0.953 landscape →
Q9QY40 — 0.952 Q9QY40 →
Q6XQN1 — 0.951 Q6XQN1 →
Q49HH9 — 0.951 Q49HH9 →
Q9EQV6 — 0.951 Q9EQV6 →
P11688 — 0.950 P11688 →
Q6P3E7 — 0.950 Q6P3E7 →